Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases

Patients with an epidermal growth factor receptor (EGFR) mutation are usually administered EGFR‐tyrosine kinase inhibitors (TKIs) as standard‐of‐care treatment. However, acquired resistance occurs between 9 and 13 months. The T790M‐resistant mutations are the most common, and osimertinib has been fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Takayuki, Itano, Hideki, Takeuchi, Mayumi, Nishimi, Yurika, Saitoh, Masahiko, Takeda, Sorou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412970/
https://www.ncbi.nlm.nih.gov/pubmed/28469919
http://dx.doi.org/10.1002/rcr2.241